dr. motzer on nivolumab/ipilimumab activity in rcc
Published 7 years ago • 426 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:25
dr. motzer discusses nivolumab for mrcc
-
1:57
dr. motzer on nivolumab versus everolimus in renal call carcinoma
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
1:27
dr. hammers on nivolumab/ipilimumab data in rcc
-
4:43
nivolumab in renal cell carcinoma
-
1:34
fda approval of frontline nivolumab/ipilimumab combo in rcc
-
1:11
dr. motzer on the milestone of immunotherapy in rcc
-
1:10
dr. motzer on first-line treatment of metastatic rcc
-
1:55
investigating responses to nivolumab and ipilimumab in advanced rcc
-
6:52
nivolumab in renal cell carcinoma
-
3:07
checkmate-214: nivolumab/ipilimumab for mrcc?
-
2:25
dr. motzer on a phase ii trial of nivolumab for mrcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
0:39
dr. atkinson on when to use nivolumab monotherapy versus nivolumab/ipilimumab combination
-
6:56
fda approves tas-102, nivolumab breakthrough in rcc, two priority reviews, and more
-
1:34
dr. sharpless on managing toxicities with nivolumab/ipilimumab in melanoma
-
1:24
dr. ernstoff discusses nivolumab and ipilimumab in advanced melanoma
-
9:09
nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced rcc
-
1:24
dr. motzer on the tivo-1 trial with tivozanib in advanced rcc